<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163916</url>
  </required_header>
  <id_info>
    <org_study_id>P10-272</org_study_id>
    <nct_id>NCT01163916</nct_id>
  </id_info>
  <brief_title>Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care</brief_title>
  <official_title>A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scientific Research Institute of Rheumatology, Moscow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Almedis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this post-marketing observational study was to obtain data on the
      characteristics (patient age/gender; disease type, severity and duration; disease specific
      treatment history; current concomitant medications; other relevant medical history) of
      patients prescribed adalimumab (Humira®) for rheumatoid arthritis (RA), ankylosing
      spondylitis (AS) and psoriatic arthritis (PsA) as part of routine clinical care in Russia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, observational study in which adalimumab is prescribed in the
      usual manner in accordance with the terms of the local marketing authorization with regards
      to dose, population and indication. No data currently exist that characterize patient types
      and adalimumab administration within the Russian population. Further, it is important to
      characterize the compliance, acceptability of patient self-injection, tolerability and safety
      profile of this therapy option with the routine clinical care.

      The total follow-up for each participant was planned to be 12 months, with approximately 6
      follow-up visits occurring at average intervals of 2-3 months. However, since this was an
      observational study, follow-up was performed according to routine clinical practice; for 127
      participants the follow-up period consisted of more than 12 months and the maximum
      observation period lasted 18.2 months. Follow-up visits were designated sequential visit
      numbers (Visit 1-6), regardless of the time point at which they occurred.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Education Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants were asked to indicate their highest education level at the Baseline visit: secondary school, vocational school or college, university graduate, current university student, or other.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Occupation</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants were asked to indicate their occupation at the Baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Residence Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants were asked to indicate their residence status within the Russian Federation at the Baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Marital Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants were asked to indicate their marital status at the Baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Disease Severity</measure>
    <time_frame>Baseline</time_frame>
    <description>Disease severity was assessed by the physician as mild, moderate or severe, based on routine clinical practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Duration of Disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Duration of disease was defined as the time from diagnosis until study entry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of Patients Prescribed Adalimumab: Other Disease Specific Treatment</measure>
    <time_frame>Baseline and at each follow-up visit (up to a maximum of 18.2 months).</time_frame>
    <description>Data on other medications (methotrexate, non-steroidal anti-inflammatory drugs [NSAIDs], corticosteroids and other medications) taken for the participant's condition (rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis) were collected at the Baseline visit and at each follow-up visit throughout the study. Overall data are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Acceptability of Self-injections</measure>
    <time_frame>Data were collected at study follow-up visits (Visits 1-6) which occurred on average at 2-3 month intervals, up to a maximum of 18.2 months.</time_frame>
    <description>At each clinic visit participants were asked to rate the convenience of adalimumab injections. Possible options were &quot;convenient,&quot; &quot;inconvenient&quot; and &quot;unable to self-inject.&quot;
The study follow-up period consisted of approximately 6 follow-up visits occurring at average intervals of 2-3 months, according to routine clinical practice.
Acceptability data are reported by follow-up visit and by treatment regimen: 40 mg every other week or 40 mg once a week, as prescribed in accordance with local marketing authorization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Missed or Delayed Injections</measure>
    <time_frame>For the duration of the study (up to a maximum of 18.2 months).</time_frame>
    <description>Compliance with prescribed adalimumab therapy was assessed by the percentage of participants with missed injections and/or injections delayed by more than 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment With Adalimumab</measure>
    <time_frame>For the duration of the study (up to a maximum of 18.2 months).</time_frame>
    <description>Tolerability to adalimumab treatment was analyzed by the time on treatment until development of an adverse event leading to adalimumab discontinuation or until discontinuation from treatment for any other reason.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">252</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Patients with RA, PsA and AS</arm_group_label>
    <description>Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
        prescribed adalimumab as part of Routine Clinical Care in Russia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients for whom adalimumab therapy is indicated according to product label and who meet
        the following criteria:

          -  Patients who are newly prescribed adalimumab therapy (no prior history of treatment
             with adalimumab) including patients with infliximab treatment history.

          -  Patients who completed Abbott sponsored interventional trials and are continuing
             treatment with commercial adalimumab thereafter.

        Exclusion Criteria:

        The following patients will not be included in the study:

          -  Patients who are being treated or will be treated with drugs at risk of interactions
             with adalimumab.

          -  Hypersensitivity to adalimumab

          -  Pregnancy

          -  Lactation

          -  Age below 18

          -  Infectious diseases including tuberculosis

          -  Patients currently participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey N Strugovschikov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50728</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50737</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6002</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50731</name>
      <address>
        <city>Izhevsk</city>
        <zip>426009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29084</name>
      <address>
        <city>Kaliningrad</city>
        <zip>236000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50746</name>
      <address>
        <city>Khanty Mansisk</city>
        <zip>628600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29163</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <zip>626200</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50736</name>
      <address>
        <city>Krasnogorsk</city>
        <zip>143420</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50727</name>
      <address>
        <city>Lipetsk</city>
        <zip>308036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50723</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50725</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50742</name>
      <address>
        <city>Moscow</city>
        <zip>109451</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50743</name>
      <address>
        <city>Moscow</city>
        <zip>109451</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50724</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50739</name>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50732</name>
      <address>
        <city>Moscow</city>
        <zip>123060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50738</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50744</name>
      <address>
        <city>Moscow</city>
        <zip>123308</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28989</name>
      <address>
        <city>Moscow</city>
        <zip>125009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28990</name>
      <address>
        <city>Moscow</city>
        <zip>125009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29195</name>
      <address>
        <city>Moscow</city>
        <zip>125009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29482</name>
      <address>
        <city>Moscow</city>
        <zip>125009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29483</name>
      <address>
        <city>Moscow</city>
        <zip>125009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50740</name>
      <address>
        <city>Moscow</city>
        <zip>127206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50733</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50745</name>
      <address>
        <city>Moscow</city>
        <zip>127543</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50741</name>
      <address>
        <city>Moscow</city>
        <zip>127642</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28956</name>
      <address>
        <city>Nizhnevartovsk</city>
        <zip>628600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28968</name>
      <address>
        <city>Perm</city>
        <zip>614014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28969</name>
      <address>
        <city>Perm</city>
        <zip>614014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 32403</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50729</name>
      <address>
        <city>Salekhard</city>
        <zip>629001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28957</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28997</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28999</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29001</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29008</name>
      <address>
        <city>Surgut</city>
        <zip>628400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 32404</name>
      <address>
        <city>Tula</city>
        <zip>300036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29095</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50734</name>
      <address>
        <city>V. Novgorod</city>
        <zip>173008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50730</name>
      <address>
        <city>Vologda</city>
        <zip>160001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50735</name>
      <address>
        <city>Voronezh</city>
        <zip>394024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 50726</name>
      <address>
        <city>Voronezh</city>
        <zip>394082</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <results_first_submitted>November 8, 2012</results_first_submitted>
  <results_first_submitted_qc>November 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2012</results_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="P2">
          <title>Psoriatic Arthritis</title>
          <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="P3">
          <title>Ankylosing Spondylitis</title>
          <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="125">One patient discontinued prior to receiving treatment with adalimumab due to absence of medication.</participants>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96">Completed 12-months treatment with adalimumab</participants>
                <participants group_id="P2" count="31">Completed 12-months treatment with adalimumab</participants>
                <participants group_id="P3" count="71">Completed 12-months treatment with adalimumab</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="B2">
          <title>Psoriatic Arthritis</title>
          <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="B3">
          <title>Ankylosing Spondylitis</title>
          <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="91"/>
            <count group_id="B4" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="13.7"/>
                    <measurement group_id="B2" value="42.4" spread="12.6"/>
                    <measurement group_id="B3" value="36.2" spread="10.6"/>
                    <measurement group_id="B4" value="42.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Education Level</title>
        <description>Participants were asked to indicate their highest education level at the Baseline visit: secondary school, vocational school or college, university graduate, current university student, or other.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis, prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Education Level</title>
          <description>Participants were asked to indicate their highest education level at the Baseline visit: secondary school, vocational school or college, university graduate, current university student, or other.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Secondary school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vocational school/college</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>University degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current university student</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Occupation</title>
        <description>Participants were asked to indicate their occupation at the Baseline visit.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Occupation</title>
          <description>Participants were asked to indicate their occupation at the Baseline visit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blue collar worker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Civil servant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White collar worker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Student</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Residence Status</title>
        <description>Participants were asked to indicate their residence status within the Russian Federation at the Baseline visit.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Residence Status</title>
          <description>Participants were asked to indicate their residence status within the Russian Federation at the Baseline visit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Permanent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Acceptability of Self-injections</title>
        <description>At each clinic visit participants were asked to rate the convenience of adalimumab injections. Possible options were &quot;convenient,&quot; &quot;inconvenient&quot; and &quot;unable to self-inject.&quot;
The study follow-up period consisted of approximately 6 follow-up visits occurring at average intervals of 2-3 months, according to routine clinical practice.
Acceptability data are reported by follow-up visit and by treatment regimen: 40 mg every other week or 40 mg once a week, as prescribed in accordance with local marketing authorization.</description>
        <time_frame>Data were collected at study follow-up visits (Visits 1-6) which occurred on average at 2-3 month intervals, up to a maximum of 18.2 months.</time_frame>
        <population>The number of participants analyzed (251) represents the total number of participants in the safety set. The number of participants with available data at each follow-up visit were: Visit 1: 249; Visit 2: 246; Visit 3: 237; Visit 4: 205; Visit 5: 179; Visit 6: 135.</population>
        <group_list>
          <group group_id="O1">
            <title>Convenient</title>
            <description>Participants who described the acceptability of adalimumab injections as &quot;convenient.&quot;</description>
          </group>
          <group group_id="O2">
            <title>Not Convenient</title>
            <description>Participants who described the acceptability of adalimumab injections as &quot;not convenient.&quot;</description>
          </group>
          <group group_id="O3">
            <title>Need Assistance</title>
            <description>Participants who were unable to self-inject.</description>
          </group>
          <group group_id="O4">
            <title>Missing</title>
            <description>Participants for whom acceptability data were not available.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Acceptability of Self-injections</title>
          <description>At each clinic visit participants were asked to rate the convenience of adalimumab injections. Possible options were &quot;convenient,&quot; &quot;inconvenient&quot; and &quot;unable to self-inject.&quot;
The study follow-up period consisted of approximately 6 follow-up visits occurring at average intervals of 2-3 months, according to routine clinical practice.
Acceptability data are reported by follow-up visit and by treatment regimen: 40 mg every other week or 40 mg once a week, as prescribed in accordance with local marketing authorization.</description>
          <population>The number of participants analyzed (251) represents the total number of participants in the safety set. The number of participants with available data at each follow-up visit were: Visit 1: 249; Visit 2: 246; Visit 3: 237; Visit 4: 205; Visit 5: 179; Visit 6: 135.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="251"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Missing regimen data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: Missing regimen data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Missing regimen data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5: Missing regimen data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: 40 mg every other week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: 40 mg once a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Missing regimen data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Missed or Delayed Injections</title>
        <description>Compliance with prescribed adalimumab therapy was assessed by the percentage of participants with missed injections and/or injections delayed by more than 7 days.</description>
        <time_frame>For the duration of the study (up to a maximum of 18.2 months).</time_frame>
        <population>Safety set; the analysis only includes participants with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Missed or Delayed Injections</title>
          <description>Compliance with prescribed adalimumab therapy was assessed by the percentage of participants with missed injections and/or injections delayed by more than 7 days.</description>
          <population>Safety set; the analysis only includes participants with non-missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No missed or delayed injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One missed or delayed injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two missed or delayed injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three or more missed or delayed injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Marital Status</title>
        <description>Participants were asked to indicate their marital status at the Baseline visit.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Marital Status</title>
          <description>Participants were asked to indicate their marital status at the Baseline visit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Disease Severity</title>
        <description>Disease severity was assessed by the physician as mild, moderate or severe, based on routine clinical practice.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Disease Severity</title>
          <description>Disease severity was assessed by the physician as mild, moderate or severe, based on routine clinical practice.</description>
          <population>Safety set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Duration of Disease</title>
        <description>Duration of disease was defined as the time from diagnosis until study entry.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Duration of Disease</title>
          <description>Duration of disease was defined as the time from diagnosis until study entry.</description>
          <population>Safety set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.70" spread="81.91" lower_limit="0.1" upper_limit="370.4"/>
                    <measurement group_id="O2" value="103.50" spread="110.02" lower_limit="13.2" upper_limit="597.3"/>
                    <measurement group_id="O3" value="50.90" spread="79.47" lower_limit="0.0" upper_limit="376.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characteristics of Patients Prescribed Adalimumab: Other Disease Specific Treatment</title>
        <description>Data on other medications (methotrexate, non-steroidal anti-inflammatory drugs [NSAIDs], corticosteroids and other medications) taken for the participant's condition (rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis) were collected at the Baseline visit and at each follow-up visit throughout the study. Overall data are presented.</description>
        <time_frame>Baseline and at each follow-up visit (up to a maximum of 18.2 months).</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Patients Prescribed Adalimumab: Other Disease Specific Treatment</title>
          <description>Data on other medications (methotrexate, non-steroidal anti-inflammatory drugs [NSAIDs], corticosteroids and other medications) taken for the participant's condition (rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis) were collected at the Baseline visit and at each follow-up visit throughout the study. Overall data are presented.</description>
          <population>Safety set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Methotrexate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment With Adalimumab</title>
        <description>Tolerability to adalimumab treatment was analyzed by the time on treatment until development of an adverse event leading to adalimumab discontinuation or until discontinuation from treatment for any other reason.</description>
        <time_frame>For the duration of the study (up to a maximum of 18.2 months).</time_frame>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis</title>
            <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O2">
            <title>Psoriatic Arthritis</title>
            <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis</title>
            <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment With Adalimumab</title>
          <description>Tolerability to adalimumab treatment was analyzed by the time on treatment until development of an adverse event leading to adalimumab discontinuation or until discontinuation from treatment for any other reason.</description>
          <population>Safety set.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.10" lower_limit="0.1" upper_limit="74.0"/>
                    <measurement group_id="O2" value="52.90" lower_limit="25.1" upper_limit="81.4"/>
                    <measurement group_id="O3" value="52.30" lower_limit="10.3" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for an average of 12 months with a maximum observation period of 18.2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis</title>
          <description>Patients with rheumatoid arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="E2">
          <title>Psoriatic Arthritis</title>
          <description>Patients with psoriatic arthritis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
        <group group_id="E3">
          <title>Ankylosing Spondylitis</title>
          <description>Patients with ankylosing spondylitis prescribed adalimumab as part of routine clinical care in Russia.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

